HEMATOLOGIC MALIGNANCY

Humoral and Cellular Immunogenicity of SHINGRIX in Hematologic Malignancy Patients 

A measure of the immune response that confers protection against herpes zoster is unknown.

Humoral Immunogenicity
Anti-gE Antibody GMCs1,*
(ATP Cohort for Immunogenicity)

Descriptive analysis.

Hematologic Malignancies Humoral Immunogenicity Anti-gE Antibody GMCs graph

Cellular Immunogenicity
Median frequency for gE-specific CD4+ T-cells1,2 †
(ATP Cohort for Immunogenicity)

Descriptive analysis.

Hematologic Malignancies Cellular Immunogenicity Median frequency for gE-specific CD4+ T-cells graph
  • *

    Error bars indicate 95% Cl.

  • †

    Error bars represent 1st and 3rd IQR.

  •  
  •  

    ATP=according to protocol; gE=glycoprotein E; GMC=geometric mean concentration; IQR=interquartile range; M=month; mlU=milli-international units; mL=milliliter.

Study Design

Study HEMATOLOGIC MALIGNANCIES [ZOSTER-039]
Phase and trial 
type/Total vaccinated cohort
 Phase 3
Randomized, observer-blind, placebo-controlled, multinational study.
N=562 [TVC*]1
Patient Population Adults with hematologic malignancies, ≥18 YOA, SHINGRIX (n=283), Placebo (n=279)1
  • Mean age 57.3 years
  • SHINGRIX: 18 to 49 YOA n=74 (26.1%), ≥50 YOA n=209 (73.9%)
  • Placebo: 18 to 49 YOA n=73 (26.2%), ≥50 YOA n=206 (73.8%)
Dosing Schedule  2-dose series (0.5 mL each) administered 1 to 2 months apart, with the first dose given during or within 6 months of completing immunosuppressive therapy1,†
Study Objectives Evaluation of immunogenicity, safety, and reactogenicity1

Patients were excluded if they were vaccinated against herpes zoster or varicella zoster virus within the 12 months preceding the first dose of study vaccine/placebo or had a clinical history of varicella or herpes zoster within the 12 months preceding the first dose of study vaccine/placebo.1

  •  

    The above is not the full list of inclusion or exclusion criteria.

  •  
  • *

    Total vaccinated cohort included all participants who received at least 1 dose of SHINGRIX or placebo.1

  • †

    For subjects who were vaccinated during a cancer therapy course, each dose was administered with at least 10 days between vaccination and cancer therapy cycles. For subjects who received the vaccination after a full cancer therapy course, the first dose was administered from 10 days to 6 months after cancer therapy had ended.1

  •  
  •  

    mL=milliliter; N=total number of patients included in the total vaccinated cohort; n=number of subjects in each group, SHINGRIX or placebo; TVC=total vaccinated cohort; YOA=years of age.

You may also be interested in:

Safety Profile

Learn about the safety profile of SHINGRIX in immunocompromised patients aged 18 years and older.

SAFETY INFO

CDC Recommendations

See what CDC says about SHINGRIX.

LEARN MORE

Storage & Dosing

Learn how to store and properly dose SHINGRIX.

SEE HOW

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Dagnew AF, llhan O, Lee WS, et al. Lancet Infect Dis. 2019:19(9):988-1000.
  2. Data on file. Study 116428 (NCT01767467). GSK Study Register. Study entry at: https://www.gskstudyregister.com/en/trial-detials/?id=116428

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET